2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Colorectal Neoplasms
408
Rectal Neoplasms
152
Colonic Neoplasms
150
Pancreatic Neoplasms
114
Stomach Neoplasms
110
Neoplasm Metastasis
88
Neoplasms
74
Esophageal Neoplasms
60
Small Cell Lung Carcinoma
45
Neuroblastoma
42
Lung Neoplasms
42
Glioblastoma
38
Carcinoma, Non-Small-Cell Lung
38
Esophageal Squamous Cell Carcinoma
33
Brain Neoplasms
33
Unspecified Adult Solid Tumor, Protocol Specific
31
Glioma
31
Breast Neoplasms
28
Central Nervous System Neoplasms
27
Adenocarcinoma Of Esophagus
27
Sarcoma
26
Gliosarcoma
22
Astrocytoma
22
Rhabdomyosarcoma
21
Sarcoma, Ewing
18
Adenocarcinoma
18
Gastrointestinal Neoplasms
17
Oligodendroglioma
16
Recurrence
14
Cholangiocarcinoma
14
Interventions
Metformin
2
Leuprolide
2
Collagenases
2
Clomiphene
2
tremelimumab
1
durvalumab
1
Temozolomide
1
Streptozocin
1
Spironolactone
1
Specimen Handling
1
Radiosurgery
1
Radiation
1
Propofol
1
Prednisone
1
Plasma Exchange
1
Nivolumab
1
Midazolam
1
Mercaptopurine
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Ipilimumab
1
Infliximab
1
Immunoglobulins
1
High-Throughput Nucleotide Sequencing
1
Heavy Ion Radiotherapy
1
Fentanyl
1
FANG vaccine
1
Data Collection
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rare Diseases
×
Irinotecan
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts